Lucid Health Consulting ISPOR 2022 Poster titled:
“Cost-Effectiveness Analysis of Arthroscopic Injection of a Bioadhesive Hydrogel Implant in Conjunction with Microfracture for the Treatment of Focal Chondral Defects of the Knee: An Australian Perspective.”
At Lucid Health Consulting, we were thrilled to be selected as a Poster Presentation at the ISPOR 2022 Global Conference in Washington, DC on May 15-18, 2022. The ISPOR Global Conference is the leading global conference for health economics and outcomes research (HEOR), for discussion and dissemination of the latest trends in healthcare.
This year’s ISPOR GLOBAL conference themed – The Future of HEOR in Patient-Driven Digital Healthcare Systems, had a “green thread” woven throughout the sessions to bring a fresh and holistic view into the future of HEOR in patient-driven digital healthcare systems.
Our Poster Presentation titled: “Cost-Effectiveness Analysis of Arthroscopic Injection of a Bioadhesive Hydrogel Implant in Conjunction with Microfracture for the Treatment of Focal Chondral Defects of the Knee: An Australian Perspective,” was presented in-person by our Director George Papadopoulos and partner Hemant Rathi.
View Lucid Health Consulting’s ISPOR 2022 Poster here:
Find out more about Lucid Health Consulting and our ISPOR 2022 Poster, contact us at:
EMAIL info@lucidhealthcon.com or PHONE +61 2-8964 9600
FOLLOW US on LINKEDIN: Lucid Health Consulting on LinkedIn
FIND OUT MORE ABOUT OUR TEAM OF EXPERT HEALTH ECONOMISTS & CONSULTANTS: OUR TEAM
AUTHOR BIO
George Papadopoulos, BSc(Hons), GDipEpi, MAICD
George is a healthcare pricing and reimbursement professional with over 25 years’ experience across in local and international healthcare companies. George worked in both local operating company and global levels in increasing levels of responsibility for leading pharmaceutical companies in Australia, Belgium and the United States. He has previously worked for Pharmacia, Johnson and Johnson, Schering-Plough and Merck. George has experience in the pharmaceutical, biotech and medical device industry, including clinical research, health economics, reimbursement, pricing and business development.
George is currently Partner and Director of Lucid Health Consulting, a strategic healthcare consultancy providing services to assist healthcare companies with the market access for their pharmaceutical, biotech, medical device or diagnostic technologies. These services include health economics strategy, health technology assessment, pricing and reimbursement strategy development and advisory board participation.
George received his BSc(Hons) from the University of Sydney and Grad Dip Epi(Pharmacoepi) from University of Newcastle. He is Past-President of the Board of ARCS; Member of Heath Economics Expert Panel of Ausbiotech and a member of HTAi (Health Technology Association International), iHEA (International Health Economics Association), ISPOR and ISPOR Australian Chapter and of the AICD (Australian Institute of Company Directors).
Recent Comments